211 related articles for article (PubMed ID: 15211433)
1. Prevention of radiocontrast-induced nephropathy.
Asif A; Epstein M
Am J Kidney Dis; 2004 Jul; 44(1):12-24. PubMed ID: 15211433
[TBL] [Abstract][Full Text] [Related]
2. Current trials of interventions to prevent radiocontrast-induced nephropathy.
Asif A; Garces G; Preston RA; Roth D
Am J Ther; 2005; 12(2):127-32. PubMed ID: 15767830
[TBL] [Abstract][Full Text] [Related]
3. Radiocontrast-induced nephropathy.
Asif A; Preston RA; Roth D
Am J Ther; 2003; 10(2):137-47. PubMed ID: 12629594
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the prevention of radiocontrast-induced nephropathy.
Marenzi G; Bartorelli AL
Curr Opin Crit Care; 2004 Dec; 10(6):505-9. PubMed ID: 15616393
[TBL] [Abstract][Full Text] [Related]
5. Clinical and experimental evidence for prevention of acute renal failure induced by radiographic contrast media.
Itoh Y; Yano T; Sendo T; Oishi R
J Pharmacol Sci; 2005 Apr; 97(4):473-88. PubMed ID: 15821342
[TBL] [Abstract][Full Text] [Related]
6. Radiocontrast-induced acute renal failure.
Weisbord SD; Palevsky PM
J Intensive Care Med; 2005; 20(2):63-75. PubMed ID: 15855219
[TBL] [Abstract][Full Text] [Related]
7. Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy.
Asif A; Epstein DL; Epstein M
J Clin Pharmacol; 2004 Dec; 44(12):1342-51. PubMed ID: 15545304
[TBL] [Abstract][Full Text] [Related]
8. [Contrast induced nephropathy].
Hörl WH
Wien Klin Wochenschr; 2009; 121(1-2):15-32. PubMed ID: 19263010
[TBL] [Abstract][Full Text] [Related]
9. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy.
Tumlin JA; Wang A; Murray PT; Mathur VS
Am Heart J; 2002 May; 143(5):894-903. PubMed ID: 12040355
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients.
Madyoon H
Rev Cardiovasc Med; 2001; 2 Suppl 1():S26-30. PubMed ID: 12439365
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy.
Kurnik BR; Allgren RL; Genter FC; Solomon RJ; Bates ER; Weisberg LS
Am J Kidney Dis; 1998 Apr; 31(4):674-80. PubMed ID: 9531185
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful.
Vogt B; Ferrari P; Schönholzer C; Marti HP; Mohaupt M; Wiederkehr M; Cereghetti C; Serra A; Huynh-Do U; Uehlinger D; Frey FJ
Am J Med; 2001 Dec; 111(9):692-8. PubMed ID: 11747848
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
[TBL] [Abstract][Full Text] [Related]
14. Radiocontrast-induced nephropathy: an update.
Perazella MA
Minerva Urol Nefrol; 2009 Sep; 61(3):215-33. PubMed ID: 19773724
[TBL] [Abstract][Full Text] [Related]
15. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration.
Marenzi G; Marana I; Lauri G; Assanelli E; Grazi M; Campodonico J; Trabattoni D; Fabbiocchi F; Montorsi P; Bartorelli AL
N Engl J Med; 2003 Oct; 349(14):1333-40. PubMed ID: 14523141
[TBL] [Abstract][Full Text] [Related]
16. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention.
Kini AA; Sharma SK
Rev Cardiovasc Med; 2001; 2 Suppl 1():S19-25. PubMed ID: 12439364
[TBL] [Abstract][Full Text] [Related]
17. Acetylcysteine for prevention of contrast nephropathy: meta-analysis.
Birck R; Krzossok S; Markowetz F; Schnülle P; van der Woude FJ; Braun C
Lancet; 2003 Aug; 362(9384):598-603. PubMed ID: 12944058
[TBL] [Abstract][Full Text] [Related]
18. Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy.
Stone GW; Tumlin JA; Madyoon H; Lepor NE; McCullough PA; Mathur VS; Murray PT; O'Neill WW
Rev Cardiovasc Med; 2001; 2 Suppl 1():S31-6. PubMed ID: 12439366
[TBL] [Abstract][Full Text] [Related]
19. [Nephropathy caused by radiocontrast media].
Kolarz M; Sułowicz W
Przegl Lek; 2005; 62(5):292-8. PubMed ID: 16334535
[TBL] [Abstract][Full Text] [Related]
20. Contrast nephropathy : an evidence-based approach to prevention.
Kandzari DE; Rebeiz AG; Wang A; Sketch MH
Am J Cardiovasc Drugs; 2003; 3(6):395-405. PubMed ID: 14728060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
